Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313359304> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W4313359304 endingPage "56.8" @default.
- W4313359304 startingPage "56.8" @default.
- W4313359304 abstract "Abstract Hepatocellular carcinoma (HCC) is the fifth common cancer in the world. In previous study, we reported that M2b monocytes which predominately generated in advanced-stage HCC patients were important target for HCC immunotherapy. Recently, an anti-PD-1 antibody has been approved for the treatment against HCC. In this study, we tried to analyzed for immunological characters of monocytes isolated from patients with several stages of HCC. From 2017 August to 2017 December, nine patients diagnosed as advanced-stage HCC patients and five patients diagnosed as early-stage HCC patients were enrolled in this study. Monocytes from peripheral blood of these patients were stained for anti-PD-1 antibody, anti-PD-L1 antibody and anti-PD-L2 antibody. These cells were analyzed for flow cytometry. Furthermore, five healthy donors were used for the control groups. In the results, a majority of monocytes from advanced-stage HCC patients were expressed PD-L1 (81.5 ± 14.7%) and PD-L2 (71.6 ± 18.5%), but not PD-1(20.2 ± 18.6%). And, monocytes from early-stage HCC patients were expressed PD-L1 (9.9 ± 4.1%), PD-L2 (38.74 ± 9.9%) and PD-1 (23.5 ± 9.8%). As the contorls, monocytes from healthy donors were not expressed PD-L1 (21.7 ± 5.5%), PD-L2 (31.7 ± 23.8%) and PD-1 (11.6 ± 6.4%). The PD-L1 expression in monocytes was increased as HCC progressed. These results indicate the PD-L1 expression may be used as a new marker for the classification of the cancer progression. And, PD-1−PD-L1+PD-L2+ monocytes which were predominantly generated in advanced-stage HCC patients, may target for the treatment of anti-PD-L1 antibody." @default.
- W4313359304 created "2023-01-06" @default.
- W4313359304 creator A5008593372 @default.
- W4313359304 creator A5016903737 @default.
- W4313359304 creator A5018505715 @default.
- W4313359304 creator A5021615645 @default.
- W4313359304 creator A5040448774 @default.
- W4313359304 creator A5047345098 @default.
- W4313359304 creator A5069290467 @default.
- W4313359304 creator A5074473576 @default.
- W4313359304 creator A5091812145 @default.
- W4313359304 date "2018-05-01" @default.
- W4313359304 modified "2023-10-16" @default.
- W4313359304 title "PD-L1 expression of monocytes may be used a new marker of the classification for the cancer progression in hepatocellular carcinoma." @default.
- W4313359304 doi "https://doi.org/10.4049/jimmunol.200.supp.56.8" @default.
- W4313359304 hasPublicationYear "2018" @default.
- W4313359304 type Work @default.
- W4313359304 citedByCount "1" @default.
- W4313359304 countsByYear W43133593042023 @default.
- W4313359304 crossrefType "journal-article" @default.
- W4313359304 hasAuthorship W4313359304A5008593372 @default.
- W4313359304 hasAuthorship W4313359304A5016903737 @default.
- W4313359304 hasAuthorship W4313359304A5018505715 @default.
- W4313359304 hasAuthorship W4313359304A5021615645 @default.
- W4313359304 hasAuthorship W4313359304A5040448774 @default.
- W4313359304 hasAuthorship W4313359304A5047345098 @default.
- W4313359304 hasAuthorship W4313359304A5069290467 @default.
- W4313359304 hasAuthorship W4313359304A5074473576 @default.
- W4313359304 hasAuthorship W4313359304A5091812145 @default.
- W4313359304 hasConcept C121608353 @default.
- W4313359304 hasConcept C126322002 @default.
- W4313359304 hasConcept C143998085 @default.
- W4313359304 hasConcept C146357865 @default.
- W4313359304 hasConcept C151730666 @default.
- W4313359304 hasConcept C159654299 @default.
- W4313359304 hasConcept C203014093 @default.
- W4313359304 hasConcept C2777701055 @default.
- W4313359304 hasConcept C2778019345 @default.
- W4313359304 hasConcept C2781053074 @default.
- W4313359304 hasConcept C553184892 @default.
- W4313359304 hasConcept C71924100 @default.
- W4313359304 hasConcept C86803240 @default.
- W4313359304 hasConcept C90924648 @default.
- W4313359304 hasConceptScore W4313359304C121608353 @default.
- W4313359304 hasConceptScore W4313359304C126322002 @default.
- W4313359304 hasConceptScore W4313359304C143998085 @default.
- W4313359304 hasConceptScore W4313359304C146357865 @default.
- W4313359304 hasConceptScore W4313359304C151730666 @default.
- W4313359304 hasConceptScore W4313359304C159654299 @default.
- W4313359304 hasConceptScore W4313359304C203014093 @default.
- W4313359304 hasConceptScore W4313359304C2777701055 @default.
- W4313359304 hasConceptScore W4313359304C2778019345 @default.
- W4313359304 hasConceptScore W4313359304C2781053074 @default.
- W4313359304 hasConceptScore W4313359304C553184892 @default.
- W4313359304 hasConceptScore W4313359304C71924100 @default.
- W4313359304 hasConceptScore W4313359304C86803240 @default.
- W4313359304 hasConceptScore W4313359304C90924648 @default.
- W4313359304 hasIssue "1_Supplement" @default.
- W4313359304 hasLocation W43133593041 @default.
- W4313359304 hasOpenAccess W4313359304 @default.
- W4313359304 hasPrimaryLocation W43133593041 @default.
- W4313359304 hasRelatedWork W2023363495 @default.
- W4313359304 hasRelatedWork W2563480852 @default.
- W4313359304 hasRelatedWork W2789659603 @default.
- W4313359304 hasRelatedWork W2899426010 @default.
- W4313359304 hasRelatedWork W3029052314 @default.
- W4313359304 hasRelatedWork W3093422519 @default.
- W4313359304 hasRelatedWork W3114360788 @default.
- W4313359304 hasRelatedWork W4226107096 @default.
- W4313359304 hasRelatedWork W4309844170 @default.
- W4313359304 hasRelatedWork W4317038016 @default.
- W4313359304 hasVolume "200" @default.
- W4313359304 isParatext "false" @default.
- W4313359304 isRetracted "false" @default.
- W4313359304 workType "article" @default.